Reagan Jarvis

Chief Executive Officer & Co-Founder Anocca

Seminars

Wednesday 17th September 2025
Spearheading the Development of TCR-Based Approaches for Inhibition of RAS-Driven Cancers in Resistant Patient Populations
4:00 pm
  • Identifying and quantifying precise HLA-peptide targets for TCR-based therapies
  • Novel specificity analysis of TCR to avoid off-target toxicities
  • Focused clinical trial designs to integrate with existing standard of care for RAS-driven malignancies
Thursday 18th September 2025
Panel Discussion: Delving into Strategies to Achieve Selective Targeting of NRAS & HRAS Mutations for Successfully Treating a Wide Array of Cancers
2:00 pm
  • Uncovering preclinical evidence to showcase the potential for NRAS and HRAS-targeting programs
  • How to selectively target NRAS or HRAS and minimize off-target effects
  • How to develop a successful patient stratification strategy for clinical trials related to NRASmutant and HRAS-mutant cancer
Reagan Jarvis